for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ABIOMED, Inc.

ABMD.O

Latest Trade

271.72USD

Change

-2.39(-0.87%)

Volume

131,925

Today's Range

264.00

 - 

274.98

52 Week Range

119.01

 - 

319.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Abiomed Reports Q2 FY 2021 Revenue Of $210 Mln

Oct 29 (Reuters) - ABIOMED Inc <ABMD.O>::ABIOMED ANNOUNCES Q2 FY 2021 REVENUE OF $210 MILLION, UP 27% OVER Q1 FY 2021 AND UP 2% OVER Q2 FY 2020 WITH 29.2% OPERATING MARGIN.Q2 GAAP EARNINGS PER SHARE $1.36.Q2 REVENUE $210 MILLION VERSUS REFINITIV IBES ESTIMATE OF $198.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.92 -- REFINITIV IBES DATA.ANTICIPATES SEQUENTIAL IMPROVEMENT IN REVENUE IN Q3 FISCAL YEAR 2021.ANTICIPATES Q3 GLOBAL REVENUE TO BE IN RANGE OF $221 MILLION TO $230 MILLION.Q3 REVENUE VIEW $234.3 MILLION -- REFINITIV IBES DATA.

ABIOMED says FDA Grants 510(K) Clearance For Co's Innovative Cardiopulmonary Support Technology

Oct 26 (Reuters) - ABIOMED Inc <ABMD.O>::FDA GRANTS 510(K) CLEARANCE FOR ABIOMED’S INNOVATIVE CARDIOPULMONARY SUPPORT TECHNOLOGY.ABIOMED INC - PLANS TO HAVE CONTROLLED LAUNCH OF BREETHE SYSTEM AT HOSPITALS IN U.S.; FULL U.S. COMMERCIAL AVAILABILITY EXPECTED IN 2021.

Abiomed Q1 GAAP Earnings Per Share $0.98

Aug 6 (Reuters) - ABIOMED Inc <ABMD.O>::ABIOMED ANNOUNCES Q1 FY 2021 REVENUE OF $165 MILLION AND 21% OPERATING MARGIN.Q1 GAAP EARNINGS PER SHARE $0.98.Q1 REVENUE $164.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $151.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.29 -- REFINITIV IBES DATA.NOT PROVIDED FULL YEAR REVENUE OR OPERATING MARGIN GUIDANCE.

FDA Approves Data Streaming From The Impella Console

July 16 (Reuters) - ABIOMED Inc <ABMD.O>::FDA APPROVES DATA STREAMING FROM THE IMPELLA CONSOLE, SETTING THE STAGE FOR ARTIFICIAL INTELLIGENCE ALGORITHMS TO FURTHER IMPROVE PATIENT OUTCOMES.

FDA Approves Abiomed’s First-In-Human Trial Of Impella ECP

June 5 (Reuters) - ABIOMED Inc <ABMD.O>::FDA APPROVES ABIOMED’S FIRST-IN-HUMAN TRIAL OF IMPELLA ECP, WORLD’S SMALLEST HEART PUMP.

Abiomed Announces Q4 FY 2020 Revenue Of $207 Million And 28.1% Operating Margin

April 30 (Reuters) - ABIOMED Inc <ABMD.O>::ABIOMED ANNOUNCES Q4 FY 2020 REVENUE OF $207 MILLION AND 28.1% OPERATING MARGIN.Q4 GAAP EARNINGS PER SHARE $0.70.Q4 REVENUE $207 MILLION VERSUS REFINITIV IBES ESTIMATE OF $207.2 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.94 -- REFINITIV IBES DATA.WILL NOT BE PROVIDING FULL YEAR 2021 REVENUE OR OPERATING MARGIN GUIDANCE AT THIS TIME.WILL ANALYZE AND MONITOR THIS DYNAMIC ENVIRONMENT AND WILL PROVIDE AN UPDATE ON GUIDANCE WHEN APPROPRIATE.COMPANY IS TAKING PROACTIVE ACTIONS TO MITIGATE BUSINESS IMPACT OF COVID-19 TO BETTER MATCH EXPENSES TO REVENUE IN Q1.HOLD ON HIRING, ELIMINATING NON-CRITICAL CONSULTANTS, CONTRACTORS, AND TEMPORARY WORKERS.REDUCING DISCRETIONARY SPENDING AND IMPLEMENTING ALTERNATE WORK SCHEDULES FOR AACHEN AND DANVERS PRODUCTION TEAMS.CEO AND COO HAVE REDUCED THEIR SALARIES BY 100%, VPS AND DIRECTORS HAVE REDUCED THEIR SALARIES BY 50% AND 20% RESPECTIVELY FOR Q1.BOARD OF DIRECTORS HAVE ALSO REDUCED THEIR CASH RETAINERS BY 50% FOR Q1.NON-DIRECTOR EMPLOYEES AT MASSACHUSETTS AND GERMAN HEADQUARTERS WILL BE TAKING A MINIMUM OF ONE-WEEK FURLOUGH OR UNUSED VACATION.FIELD TEAM WILL WORK ON MONTHLY OPERATING PLANS TO ALLOW FOR FLEXIBILITY AND POTENTIAL TO INCREASE SEQUENTIALLY EACH WEEK.

Abiomed Announces Q3 Earnings Per Share $1.51

Feb 6 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCES Q3 FY 2020 REVENUE OF $222 MILLION AND 31.7% OPERATING MARGIN.Q3 GAAP EARNINGS PER SHARE $1.51.Q3 REVENUE $222 MILLION VERSUS REFINITIV IBES ESTIMATE OF $227 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.09 -- REFINITIV IBES DATA.COMPANY REVISED ITS 2020 REVENUE GUIDANCE TO BE IN THE RANGE OF $846 MILLION TO $877 MILLION, AN INCREASE OF 10% TO 14%.

Abiomed Reports Preliminary Q3 Revenue Of $222 Mln

Jan 13 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2020 REVENUE OF $222 MILLION, UP 10% OVER PRIOR YEAR.Q3 REVENUE $222 MILLION VERSUS REFINITIV IBES ESTIMATE OF $226.7 MILLION.UPDATING ITS FISCAL YEAR 2020 REVENUE GUIDANCE TO BE IN RANGE OF $846 MILLION TO $877 MILLION.FY2020 REVENUE VIEW $885.8 MILLION -- REFINITIV IBES DATA.

Abiomed Announces Q2 FY 2020 Revenue Of $205 Million And 29.4% Operating Margin

Oct 31 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCES Q2 FY 2020 REVENUE OF $205 MILLION AND 29.4% OPERATING MARGIN.SEES FY 2020 REVENUE $885 MILLION TO $925 MILLION.Q2 REVENUE $205 MILLION VERSUS REFINITIV IBES ESTIMATE OF $206.4 MILLION.Q2 GAAP EARNINGS PER SHARE $0.28.Q2 EARNINGS PER SHARE ESTIMATE $0.93 -- REFINITIV IBES DATA.MAINTAINING ITS FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 28% TO 30%.

FDA Post Approval Study Demonstrates Timely Identification Of Right Heart Failure And Early Use Of Impella Rp Leads To Higher Survival

Oct 25 (Reuters) - Abiomed Inc <ABMD.O>::FDA POST APPROVAL STUDY DEMONSTRATES TIMELY IDENTIFICATION OF RIGHT HEART FAILURE AND EARLY USE OF IMPELLA RP LEADS TO HIGHER SURVIVAL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up